UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000061464
Receipt number R000070337
Scientific Title A study evaluating the effects of a test food on blood ketone levels and safety in healthy adult men
Date of disclosure of the study information 2026/05/07
Last modified on 2026/05/08 14:11:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study evaluating the effects of a test food on blood ketone levels and safety in healthy adult men

Acronym

Ketone body dynamics and safety of after single-dose intake of test food (healthy men)

Scientific Title

A study evaluating the effects of a test food on blood ketone levels and safety in healthy adult men

Scientific Title:Acronym

Ketone body dynamics and safety of after single-dose intake of test food (healthy men)

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To assess the kinetics of blood ketone levels and the safety following a single administration of the test food in healthy adult men

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

ketone bodies fractionation

Key secondary outcomes

urinary ketone bodies, blood glucose, venous blood gas analysis (pH, PO2, PCO2, HCO3-, BE)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

4

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Single dose of 200 mL of the test food

Interventions/Control_2

Single dose of 400 mL of the test food

Interventions/Control_3

Single dose of 600 mL of the test food

Interventions/Control_4

Single dose of 200 mL of the placebo food

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

40 years-old >

Gender

Male

Key inclusion criteria

(1) Healthy adult males aged >= 20 and < 40 years
(2) Subjects with a BMI of 18.5 kg/m2 or higher but less than 25.0 kg/m2 at the time of the baseline assessment
(3) Subjects judged to be healthy based on baseline assessment results
(4) Subjects who fully understand the purpose and content of the study and voluntarily agree to participate in the study

Key exclusion criteria

(1) Subjects receiving treatment with any therapeutic drug
(2) Subjects following diet and exercise therapy under a physician's supervision
(3) Subjects with a current serious illness
(4) Subjects with a history of gastrointestinal surgery (excluding appendectomy) or gastrointestinal disorders
(5) Subjects with a smoking habit
(6) Subjects regularly using medications, quasi-drugs, or health foods (e.g., FOSHU, foods with functional claims, supplements) three or more times weekly
(7) Subjects adhering to dietary restrictions such as low-carbohydrate, low-protein, or ketogenic diets
(8) Subjects with a history of food or drug allergies
(9) Subjects participating in other clinical studies, or who completed another clinical study within one month prior to enrollment
(10) Subjects who underwent blood sampling of more than 200 mL or 400 mL within one month prior to study start
(11) Subjects who work in shifts, work late at night, and have an irregular daily rhythm
(12) Subjects who tested positive for infection in screening performed upon admission for hospitalization
(13) Subjects who are judged to be unsuitable for participation in the study based on their responses to the lifestyle questionnaire
(14) Subjects deemed ineligible for participation based on baseline assessment results
(15) Subjects who are judged as unsuitable for the study by the principal investigator or the investigator for other reason

Target sample size

24


Research contact person

Name of lead principal investigator

1st name Toru
Middle name
Last name Nakamura

Organization

EN Otsuka Pharmaceutical Co., Ltd.

Division name

Clinical Development Department

Zip code

101-0052

Address

6th Floor, Nikko Kanda Building, 1-1 Kanda Ogawamachi Chiyoda-ku, Tokyo,

TEL

03-6632-3516

Email

nakamura.toru@otsuka.jp


Public contact

Name of contact person

1st name Saki
Middle name
Last name Fukuchi

Organization

EP Mediate Co., Ltd.

Division name

Development Department Trial Planning Section

Zip code

162-0814

Address

Acropolis Tokyo, 6-29 Shinogawacho, Shinjuku, Tokyo,

TEL

090-1400-7556

Homepage URL


Email

fukuchi.saki473@eps.co.jp


Sponsor or person

Institute

EP Mediate Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

EN Otsuka Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Station Clinic Research Ethics Committee

Address

3-12-8, Takaban, Meguro-ku, Tokyo

Tel

03-6452-2712

Email

epmd_fd-erb@eps.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団成守会 成守会クリニック(東京都)


Other administrative information

Date of disclosure of the study information

2026 Year 05 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2026 Year 04 Month 09 Day

Date of IRB

2026 Year 04 Month 09 Day

Anticipated trial start date

2026 Year 05 Month 08 Day

Last follow-up date

2026 Year 06 Month 07 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 05 Month 07 Day

Last modified on

2026 Year 05 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000070337